SK Biopharmaceuticals, a biotech firm specializing in central nervous system disorders and oncology, has announced the establishment of a new joint venture named Mentis Care, Inc. This collaboration is with Eurofarma, a prominent Brazilian pharmaceutical company with operations in 24 countries, including North America, Latin America, and Africa. The venture aims to commercialize an AI-driven platform specifically designed for managing epilepsy. The official launch took place on October 20, 2025, in Toronto, Canada, marking a significant step in the company”s expansion into digital healthcare.
Located in the MaRS Discovery District, one of North America”s largest innovation hubs, Mentis Care will leverage SK Biopharmaceuticals” expertise in AI-based electroencephalography (EEG) and wearable technologies that aid in real-time seizure detection and monitoring. The platform will integrate real-time seizure detection with predictive algorithms and clinical decision support tools, enhancing personalized patient care.
Since 2018, SK Biopharmaceuticals has focused on developing advanced technologies for seizure detection. The collaboration with Eurofarma, which began in 2022 with the development of the anti-seizure medication cenobamate (marketed as XCOPRI® in the U.S.), has now expanded to include digital healthcare initiatives through this joint venture.
Hassan Kotob, formerly the CEO of Brain Scientific, has been appointed as the Chief Executive Officer of Mentis Care. With extensive experience in healthcare and technology, Kotob will lead the development of this innovative platform that aims to revolutionize the management of seizures and related neurological events.
“Mentis Care is an AI-driven digital health company with the mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring,” said Kotob. He emphasized the goal of setting a new global standard in digital epilepsy management.
Rodrigo Pereira, Global Executive Director of Entrepreneurship and Digital at Eurofarma, remarked that this joint venture represents the future of healthcare, integrating digital technologies with traditional medicine to significantly improve patient outcomes. Eurofarma is recognized for its comprehensive CNS treatment options in Latin America and aims to enhance its digital innovation investments through this partnership.
Donghoon Lee, CEO of SK Biopharmaceuticals, stated that the company is venturing beyond pharmaceuticals into the realm of digital healthcare to create new opportunities in patient care. He highlighted the importance of integrating AI and clinical data to enhance epilepsy treatment.
SK Life Science, Inc., based in Paramus, New Jersey, is the U.S. subsidiary of SK Biopharmaceuticals Co., Ltd. Together, they focus on advancing innovative treatments for CNS disorders and oncology, with multiple compounds currently under development. SK Biopharmaceuticals is part of the SK Group, one of South Korea”s largest conglomerates, which is committed to sustainability and innovation across various sectors.
Eurofarma, established in 1972, operates in the healthcare sector, producing and commercializing a wide range of pharmaceutical products aimed at enhancing quality of life. The company is a leader in medical prescriptions in Brazil and has a broad portfolio that includes over 4,000 SKUs across numerous medical specialties.
Mentis Care aims to transform neurological care with its predictive AI platform, a first of its kind designed for real-time detection and forecasting of seizures and other neurological events. The venture aspires to offer patients and families increased safety and confidence, thereby setting a new standard in brain health and digital neuromonitoring.
In addition, cenobamate, the antiseizure medication developed by SK Biopharmaceuticals, works through a unique dual mechanism of action to reduce neuronal excitability, although the exact therapeutic mechanism remains unknown. It is marketed under various brand names globally, reflecting SK Biopharmaceuticals” commitment to addressing the needs of epilepsy patients worldwide.
